Reviewed and revised 30 March 2015
An adaptive clinical trial involves a study design in which key characteristics are adjusted while enrollment in the trial is ongoing using prospectively defined decision rules and in response to information arising from the data accumulating in the trial
- Adjustable key characteristics include: randomization ratio, number of treatment groups, number and frequency of interim analyses, and the patient subpopulation being considered
- All possible changes must be pre-specified to achieve standard statistical operating characteristics, including controlling the trial’s false-positive rate
- Understanding the performance characteristics of an adaptive trial requires extensive numerical simulation under varying assumptions regarding true treatment effects
- Knowledge regarding the relative effectiveness of the treatments involved accumulates over the course of a clinical trial, beginning with a state of equipoise and having high confidence near the end
- Fixed assignment, as occurs in a traditional RCT, ensures that this information is ignored and a fixed proportion of patients will receive a potentially inferior therapy (assuming there is a difference between the comparison therapies)
- Interim information available in a trial can be used to improve the outcomes of trial participants, especially those who enroll later in the trial thus increasing the probability that future trial participants are assigned to the study group with a better expected outcome
- Study outcomes may also be obtained more efficiently
PROS AND CONS
- An adaptive clinical trial design can be used to increase the likelihood that study participants will benefit by being in a clinical trial (e.g. if there is a potential interaction between baseline characteristics and the treatment effect, different allocation ratios can be used for different patient subgroups)
- fewer patients needed
- avoids problems resulting from errors such as misestimates of the optimal dose, or overly optimistic or pessimistic estimates in placebo group primary outcome event rate
- more efficient
- less expensive
- complexity of study design and trial conduct
- longer design phase (involving numerical simulations)
- concerns about the introduction of bias
- understanding of funding agencies and peer reviewers
- lack of experience and knowledge among trial stakeholders
Roger Lewis provides an overview of Adaptive Trial Designs here:
References and Links
- Chow SC, Chang M. Adaptive design methods in clinical trials – a review. Orphanet J Rare Dis. 2008 May 2;3:11. PMC2422839.
- Kairalla JA, Coffey CS, Thomann MA, Muller KE. Adaptive trial designs: a review of barriers and opportunities. Trials. 2012 Aug 23;13:145. PMC3519822.
- Lee JJ, Chu CT. Bayesian clinical trials in action. Stat Med. 2012 Nov 10;31(25):2955-72. PMC3495977.
- Meurer WJ, Lewis RJ, Tagle D, Fetters MD, Legocki L, Berry S, Connor J, Durkalski V, Elm J, Zhao W, Frederiksen S, Silbergleit R, Palesch Y, Berry DA, Barsan WG. An overview of the adaptive designs accelerating promising trials into treatments (ADAPT-IT) project. Ann Emerg Med. 2012 Oct;60(4):451-7. PMC3557826.
- Meurer WJ, Lewis RJ, Berry DA. Adaptive clinical trials: a partial remedy for the therapeutic misconception? JAMA. 2012 Jun 13;307(22):2377-8. PMID: 22692168.
FOAM and web resources
- FET — Adaptive and Bayesian Trial Design in EM Research by Roger Lewis (2012)
- ICN — Adaptive Trial Designs (2014)
Chris is an Intensivist and ECMO specialist at the Alfred ICU in Melbourne. He is also the Innovation Lead for the Australian Centre for Health Innovation at Alfred Health, a Clinical Adjunct Associate Professor at Monash University, and the Chair of the Australian and New Zealand Intensive Care Society (ANZICS) Education Committee. He is a co-founder of the Australia and New Zealand Clinician Educator Network (ANZCEN) and is the Lead for the ANZCEN Clinician Educator Incubator programme. He is on the Board of Directors for the Intensive Care Foundation and is a First Part Examiner for the College of Intensive Care Medicine. He is an internationally recognised Clinician Educator with a passion for helping clinicians learn and for improving the clinical performance of individuals and collectives.
After finishing his medical degree at the University of Auckland, he continued post-graduate training in New Zealand as well as Australia’s Northern Territory, Perth and Melbourne. He has completed fellowship training in both intensive care medicine and emergency medicine, as well as post-graduate training in biochemistry, clinical toxicology, clinical epidemiology, and health professional education.
He is actively involved in in using translational simulation to improve patient care and the design of processes and systems at Alfred Health. He coordinates the Alfred ICU’s education and simulation programmes and runs the unit’s education website, INTENSIVE. He created the ‘Critically Ill Airway’ course and teaches on numerous courses around the world. He is one of the founders of the FOAM movement (Free Open-Access Medical education) and is co-creator of LITFL.com, the RAGE podcast, the Resuscitology course, and the SMACC conference.
His one great achievement is being the father of two amazing children.
On Twitter, he is @precordialthump.